ClinicalTrials.gg
RecruitingNCT06323824Updated Sep 14, 2026

Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.

A Phase 4 interventional study of Methadone and Buprenorphine (BUP) in Opioid Use Disorder, sponsored by Yale University. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Yale University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing methadone in Opioid-Related Disorders — 4 open to participants now, 4 under way, 1 of them phase 3. Methadone · Opioid-Related Disorders.

Planned enrollment
Largest of 19
600 · median 68
Started
2024
the only one that year
Phase 4
5 of 19
2 open now
Registered
17th of 19
by date
Lead sponsor
3 of 19
Yale University

Among the 19 studies testing methadone in Opioid-Related Disorders, this one has the largest planned enrollment, is the only one that started in 2024, is one of 5 in phase 4, and was the 17th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 19 studies testing methadone in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing methadone in Opioid-Related Disorders, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone.

Read the detailed description

This study is a randomized, pragmatic hybrid type 1 effectiveness/implementation multisite (approximately 6 sites) trial to determine whether office-based methadone with pharmacy administration and/or dispensing or buprenorphine (BUP) results in greater treatment retention in approximately 600 patients with opioid use disorder (OUD). This trial will also identify implementation barriers, facilitators and acceptability at the patient, provider and health-systems level for office-based methadone with pharmacy administration and/or dispensing.

An ancillary extended study was added to this trial in January of 2026. A sub-set of current participants that were receiving office based methadone as of day 168 of the parent study will continue to be followed for other pre-specified outcomes.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • Opioid Use Disorder
  • Methadone
  • Buprenorphine
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older;
  • Meet , 5th Edition (DSM-5) criteria for OUD;
  • Are initiating a new MOUD treatment episode

Exclusion criteria

Exclusion Criteria

  • Have been prescribed (and ingested) or been administered more than 72 hours of MOUD in the 7 days prior to randomization as a "bridge" to the new OUD treatment episode. Such MOUD may include prescribed (and ingested) or administered medically managed withdrawal (aka detoxification).
  • Known to methadone or BUP
  • Unwilling to pursue or continue pre-natal care or pregnancy counseling if determined pregnant by urine human chorionic gonadotropin (hCG) testing at the screening assessment
  • Be actively suicidal or severely cognitively impaired (e.g., dementia, untreated psychosis) precluding as determined by site clinician
  • Current severe comorbid substance use disorder requiring residential or inpatient treatment services as determined by site clinician
  • Be unable to provide locator information including one or more contacts in addition to themselves
  • Be unwilling to follow study procedures (e.g., unwilling to receive treatment from site clinician, use the study pharmacy, unwilling to be randomized to BUP or methadone, or will be unavailable for the follow-up assessments) including allowing the researchers to access their record in the EMR and state's prescription drug monitoring program
  • Have previously enrolled in CTN-0131
  • Currently enrolled in another research study which will conflict with study procedures
  • Are currently in jail, prison or other overnight facility as required by a court of law or have pending legal action that could prevent participation in study activities
  • Unable to conduct research assessments in English as determined by Site PI or their designee.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Office-based methadone

    Under special Drug Enforcement Administration (DEA) exception, Clinician prescribes methadone and oral methadone is administered and/or dispensed at a pharmacy which also has an exception to do so. All randomized controlled trial (RCT) participants are offered additional behavioral treatments (e.g., individual, group, telehealth, phone-based).

    Drug: Methadone

  • Active comparator
    Office-based buprenorphine (BUP)

    Clinician prescribes BUP formulations that are dispensed at a pharmacy or administered in the office (e.g., extended-release formulations). All RCT participants are offered additional behavioral treatments (e.g., individual, group, telehealth, phone-based).

    Drug: Buprenorphine (BUP)

Interventions

  • Drug: Methadone Possible formulations: 10 and 50 mg tablets

  • DrugBuprenorphineStudies of BuprenorphineBuprenorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: Buprenorphine (BUP) Possible formulations: A. Buprenorphine, 225 mcg to 24 mg, 225 mcg to 32 mg per day, B. Buprenorphine (Extended release), 300 mg q 28 days (Sublocade), 100 mg q 28 days (Sublocade), 8 mg q 7 days (Brixadi), 16 mg q 7 days (Brixadi), 24 mg q 7 days (Brixadi), 32 mg q 7 days (Brixadi), 64 mg q 28 days (Brixadi), 96 mg q 28 days (Brixadi), 128 mg q 28 days (Brixadi),

06

What researchers measure

Primary outcomes

  1. Number of days of continuous treatment with site clinician-prescribed methadone or buprenorphine, as randomized, during the 168 days post-randomization among RCT participants.

    This measure is based on PDMP data for methadone and non-injectable buprenorphine and EMR data for injectable buprenorphine formulations

    Time frame: up to Day 168

Secondary outcomes

  1. Number of self-reported continuous treatment days in any FDA-approved formulation of MOUD treatment during the 168 days post-randomization.

    This measure is assessed using the MOUD Calendar Based Recall Recall Instruments.

    Time frame: up to Day 168

  2. Number of self-reported continuous treatment days in formal OUD treatment, according to American Society of Addiction Medicine (ASAM) levels of care 1-4, during the 168 days post-randomization.

    This measure is assessed using one or more of the following: The Health Services Utilization instrument, a brief structured interview regarding health care utilization (inpatient and outpatient) collecting information on the type and amount of services received, Timeline Followback Medications, MOUD Calendar Based Recall, and Treatment Dates instruments.

    Time frame: up to Day 168

  3. Total number of days receiving any FDA-approved MOUD formulation during the 168 days post-randomization.

    This measure is assessed using EMR (for injectable MOUD formulations) and PDMP data.

    Time frame: up to Day 168

  4. The longest duration of continuous treatment episode with MOUD, as randomized, during the 168 days post randomization.

    This measure is based on PDMP and/or EMR data.

    Time frame: up to Day 168

  5. Total number of days receiving methadone or buprenorphine, during the 168 days post-randomization.

    This measure is assessed using EMR (for injectable MOUD formulations) and PDMP data.

    Time frame: up to Day 168

  6. Total number of days of self-reported non-prescribed opioid use during each 28-day assessment period.

    This measure is assessed by the Opioid Use Calendar Based Recall instruments.

    Time frame: up to Day 168

  7. Total number of days of self-reported non-prescribed stimulant use during each 28-day assessment period.

    This measure is assessed by the Timeline Followback instrument.

    Time frame: up to Day 168

  8. Total number of days of self-reported non-prescribed benzodiazepine use during each 28-day assessment period.

    This measure is assessed by the Timeline Followback instrument.

    Time frame: up to Day 168

  9. Urine toxicology

    Total number of monthly (28 days) urines negative for non-prescribed opioids during the 168 days post-randomization. Non-prescribed opioids will be determined using the Opioid Use Calendar Based Recall instrument.

    Time frame: up to Day 168

  10. Participant satisfaction with MOUD

    Proportion of RCT participants who report at the assessment scheduled to be collected on day 28 that the medication they received was at least "Somewhat helpful" on the Satisfaction with MOUD Provider Scale instrument.

    Time frame: up to Day 168

  11. Total number of self-reported overdose events per total number of participant days at risk.

    The Overdose Calendar Recall instrument collects overdose events.

    Time frame: up to Day 168

  12. Total number of self-reported injection drug use related events during each 28-day assessment period.

    Assessment of Infectious or Other Complications of Injection Drug Use assess for skin abscesses, ulcers , cellulitis, osteoarticular septic arthritis, osteomyelitis, epidural infection , endovascular, new injection-related viral infections diagnosis of Hepatitis or HIV.

    Time frame: Up to Day 168

  13. Mean score Pain measured using Pain, Enjoyment of Life and General Activity (PEG) Scale (PEG-3)

    Mean scores on the PEG-3 instrument over time. The PEG-3 instrument is collected every 28 days. The mean score is the average of the three 0-10 rated items. Total score range 0-10. Higher scores indicate worse pain.

    Time frame: Up to Day 168

  14. Total number of self-reported days with acute care utilization (ED or hospitalization) during each 28-day assessment period.

    The Health Services Utilization instrument is a brief, structured interview regarding health care utilization (inpatient and outpatient) collecting information on the type and amount of services received. This includes ED visits, hospitalizations, primary medical care visits (excluding those for BUP treatment) and self-help sources of support (e.g., NA). Also assessed are receipt of formal and informal addiction and mental health treatment services RCT participants might have received outside the study interventions.

    Time frame: Up to Day 168

  15. Total number of behavioral counseling service visits attended per participant during each 28-day assessment period.

    Assessed by EMR extraction and the Health Services Utilization.

    Time frame: Up to Day 168

  16. Total number of planned prescriber visits attended during each 28-day assessment period.

    Assessed by EMR extraction.

    Time frame: Up to Day 168

  17. Pharmacist practice fidelity

    Assessed by MOUD Visit Checklist completion over time. The MOUD Visit Checklist collects clinical activities that might be performed by a pharmacist at each pharmacy, such as performing medication reconciliation; conducting safety assessments, adverse effects of methadone, recent overdose events, checking the patient's controlled medications prescription status using the PDMP before dispensing methadone; providing patient education/counseling; communicating with the clinician regarding any concern; and administering one methadone dose at the pharmacy and/or dispensing methadone according to the prescription.

    Time frame: Up to Day 168

Other outcomes

  1. Retention in office-based methadone treatment

    Retention will be defined as the number of days of continuous office-based methadone treatment (time to event outcome) staring at day 168. Discontinuation of methadone for the extended study component will be defined as more than a self-reported 30-day gap in receipt of methadone or non-response on two consecutive 60-day assessments. The date of discontinuation will be the end of the last 30-day period with any self-reported office-based methadone treatment. Participants who remain in continuous treatment through the end of the study and will be censored on day of the last 60 day assessment. Only collected in extended study participants.

    Time frame: Starting at day 168 post enrollment up to 2years

  2. Percentage of days covered of self-reported pharmacy dispensed methadone treatment

    Percentage of days covered of self-reported pharmacy dispensed methadone treatment (i.e., number of self-reported days covered per total days observed). Only collected in extended study participants.

    Time frame: starting at day 168 post enrollment up to 2 years

  3. Total number of self-reported overdose events

    To assess overdose events, participants will self-report the number of overdose events in the past 28 days. Only collected in extended study participants.

    Time frame: Starting at day 168 post enrollment up to 2years

  4. Methadone dose

    Participants will self-report the most recent daily dose (in milligrams) of methadone prescribed and obtained from the pharmacy. Only collected in extended study participants.

    Time frame: Starting at day 168 post enrollment up to 2years

  5. Days of treatment

    Days of treatment will be the count of self-reported number of days the participant self reported taking prescribed methadone. Only collected in extended study participants.

    Time frame: Starting at day 168 post enrollment up to 2years

  6. Treatment Effectiveness Assessment (TEA)

    The TEA collects self-report data across four domains: substance use, health, lifestyle, and community. This will be analyzed as a repeated measure of overall numerical score. Total score range 4-40. higher scores mean greater improvement. Only collected in extended study participants.

    Time frame: Starting at day 168 post enrollment up to 2years

  7. Health service utilization

    Participants will be asked to report the inpatient and outpatient services they used in the past 28 days. Only collected in extended study participants.

    Time frame: Starting at day 168 post enrollment up to 2years

  8. Health related quality of life

    To assess health related quality of life, participants will self-report their general health, physical health, and mental health during the past 28 days. This will be analyzed as a repeated measure of overall numerical score. Only collected in extended study participants.

    Time frame: Starting at day 168 post enrollment up to 2years

  9. Crime and criminal justice involvement

    To assess crime and criminal justice, participants will self-report how many days in the past 60 days they have been incarcerated, if they have been in contact with the court, criminal justice system, or probation/parole officer and how many of those days in the past 60 they were incarcerated, in contact with the court, criminal justice system or probation/parole officer. Criminal justice involvement will be defined as the percentage of days of self-reported involvement (i.e., number of self-reported days per total days observed). Only collected in extended study participants.

    Time frame: Starting at day 168 post enrollment up to 2years

  10. End of study status

    End of study status for participants which includes; office-based methadone treatment at end of study, withdrew consent, deceased, unable to contact, no longer being prescribed methadone from the site. End of study status will be reported by study site Research Associates or Site Clinicians. Only collected in extended study participants.

    Time frame: Starting at day 168 post enrollment up to 2years

  11. Substance use

    To assess substance use, participants will self-report how many of the past 60 days that they used a substance. Monthly substance use obtained through survey assessment at each 60- day assessment. Total number of days of self-reported substance use during each 60 day assessment period (discrete or continuous outcome, repeated measure). Only collected in extended study participants.

    Time frame: Starting at day 168 post enrollment up to 2years

07

Study locations

6 of 6 sites recruiting
  • Highland Hospital Bridge Clinic at Alameda Health System
    Oakland, California 94602, United States
    Recruiting
  • Outpatient Buprenorphine Induction Clinic, University of California, San Francisco
    San Francisco, California 94103, United States
    Recruiting
    • Kristina Toma · ContactEMBOSS@ucsf.edu · 415-254-0398
    • Paula Lum, MD · Principal investigator
    • Andy Tompkins, MD · Principal investigator
    • Christine Soran, MD · Sub investigator
  • Rapid Start Clinic, Kaiser Permanente Colorado
    Denver, Colorado 80205, United States
    Recruiting
    • Jennifer Barrow · ContactEMBOSS@kp.org · (303)-739-3666
    • Ingrid Binswanger, MD · Principal investigator
  • Officed Based Addiction Treatment Program, Boston Medical Center
    Boston, Massachusetts 02118, United States
    Recruiting
    • Emily Oot · ContactEMBOSS@bmc.org · 857-283-7620
    • Zoe Weinstein, MD · Principal investigator
  • Hennepin Healthcare Addiction Medicine
    Minneapolis, Minnesota 55415, United States
    Recruiting
  • Marshall University Division of Addiction Sciences P.R.O.A.C.T
    Huntington, West Virginia 25703, United States
    Recruiting
    • Brynn M Taylor · Contacttaylor975@marshall.edu · 740-302-0845
    • Zachary Hansen, MD · Principal investigator
    • Todd Davies, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The National Institute on Drug Abuse (NIDA) Data Share web site is an electronic environment that allows data from completed clinical trials to be distributed to investigators and the public in order to promote new research, encourage further analyses, and disseminate information to the community. Secondary analyses produced from data sharing multiply the scientific contribution of the original research. NIH expects and supports the timely release and sharing of final research data from NIH-supported studies for use by other researchers to expedite the translation of research results into knowledge, products and procedures to improve human health.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data sets will be available after (1) the primary paper has been accepted for publication, or (2) the data is locked for more than 18 months, whichever comes first.

Access criteria: Public

Data sharing details ↗ · datashare.nida.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2028, 54 months after the start.

Of 48 non-industry phase 4 interventional studies under Opioid-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's planned 54 months is above that.

Counting every sponsor, half of 52 studies reached it within 32 months; a quarter within 20 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 21, 2024
StartActual
Jun 4, 2024
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06323824
Lead sponsor
Yale University
Collaborators
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), The Emmes Company, LLC, University of California, San Francisco, Boston Medical Center (BMC), Hennepin Healthcare Research Institute, Alameda Health System, Marshall Health, Kaiser Permanente
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Jun 4, 2024
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 14, 2026

Study contacts

Jessica Research Associate
Contact
j.mckenzie@yale.edu
203-785-6821
Melissa Gordon
Contact
melissa.gordon@yale.edu
203-937-3486 ext. 7415
David Fiellin, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion